Retatrutide is a highly promising investigational peptide, primarily for the treatment of obesity and Type 2 diabetes mellitus.

It represents a breakthrough as a triple hormone receptor agonist (nicknamed the "Triple G") because it is the first peptide in development to simultaneously target three key metabolic pathways:

1. GLP-1 (Glucagon-like peptide-1) Receptor: Suppresses appetite, slows digestion, and enhances insulin release.
2. GIP (Glucose-dependent insulinotropic polypeptide) Receptor: Improves insulin sensitivity and aids in fat metabolism and blood sugar reduction.
3. Glucagon Receptor (GCGR): This unique third component promotes the breakdown of stored fat for energy (lipolysis) and increases energy expenditure.